Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer.

[1]  M. Spahn,et al.  Debulking surgery in the setting of very high‐risk prostate cancer scenarios , 2012, BJU international.

[2]  R. Orecchia,et al.  Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[3]  B. Hickey,et al.  Adjuvant radiotherapy following radical prostatectomy for prostate cancer. , 2011, The Cochrane database of systematic reviews.

[4]  U. Capitanio,et al.  Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. , 2011, European urology.

[5]  P. Tamboli,et al.  Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. , 2011, European urology.

[6]  M. Borghesi,et al.  The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate‐ and high‐risk prostate cancer , 2011, BJU international.

[7]  C. Wood,et al.  The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. , 2011, Hematology/oncology clinics of North America.

[8]  R. Henke,et al.  Complete PSA Remission without Adjuvant Therapy after Secondary Lymph Node Surgery in Selected Patients with Biochemical Relapse after Radical Prostatectomy and Pelvic Lymph Node Dissection , 2011, Advances in urology.

[9]  V. Laudone,et al.  Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. , 2010, The Journal of urology.

[10]  M. Pocard,et al.  A Comparative Study of Complete Cytoreductive Surgery Plus Intraperitoneal Chemotherapy to Treat Peritoneal Dissemination From Colon, Rectum, Small Bowel, and Nonpseudomyxoma Appendix , 2010, Annals of surgery.

[11]  Jan Pruim,et al.  Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. , 2010, International journal of radiation oncology, biology, physics.

[12]  V. Bettinardi,et al.  Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  F. Fazio,et al.  DETECTION OF LYMPH-NODE METASTASES WITH INTEGRATED [11C]CHOLINE PET/CT IN PATIENTS WITH PSA FAILURE AFTER RADICAL RETROPUBIC PROSTATECTOMY: VALIDATION BY OPEN PELVIC-RETROPERITONEAL LYMPHADENECTOMY , 2009 .

[14]  F. Mottaghy,et al.  [11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy , 2009, World Journal of Urology.

[15]  Roland Bares,et al.  Histological verification of 11C‐choline‐positron emission/computed tomography‐positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer , 2008, BJU international.

[16]  E. Adang,et al.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.

[17]  F. Montorsi,et al.  TWO POSITIVE NODES REPRESENT A SIGNIFICANT CUT-OFF VALUE FOR CANCER SPECIFIC SURVIVAL IN PATIENTS WITH NODE POSITIVE PROSTATE CANCER. A NEW PROPOSAL BASED ON A TWO INSTITUTION EXPERIENCE ON 784 CONSECUTIVE N+ PATIENTS , 2008 .

[18]  Misop Han,et al.  Contemporary evaluation of the D'amico risk classification of prostate cancer. , 2007, Urology.

[19]  F. Mottaghy,et al.  Evaluation of [11C]‐choline positron‐emission/computed tomography in patients with increasing prostate‐specific antigen levels after primary treatment for prostate cancer , 2007, BJU international.

[20]  F. Fazio,et al.  Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. , 2007, European urology.

[21]  P. Carroll,et al.  Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation , 2007, Cancer.

[22]  B. Rini,et al.  The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. , 2007, The Journal of urology.

[23]  Jie Cai,et al.  Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. , 2004, The Journal of urology.

[24]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[25]  Steven Piantadosi,et al.  Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.

[26]  C. Higano.  Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. , 2003, Urology.

[27]  A. V. von Eschenbach,et al.  Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. , 2001, Urology.

[28]  M. Zerbib,et al.  A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. , 1996, Urology.

[29]  P. Schellhammer,et al.  A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. , 1995, Urology.

[30]  U. Studer,et al.  The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. , 2008, European urology.

[31]  R. Benson.  Total androgen blockade: the United States experience. , 1993, European urology.